AU2005250146B2 - HIV type and subtype detection - Google Patents
HIV type and subtype detection Download PDFInfo
- Publication number
- AU2005250146B2 AU2005250146B2 AU2005250146A AU2005250146A AU2005250146B2 AU 2005250146 B2 AU2005250146 B2 AU 2005250146B2 AU 2005250146 A AU2005250146 A AU 2005250146A AU 2005250146 A AU2005250146 A AU 2005250146A AU 2005250146 B2 AU2005250146 B2 AU 2005250146B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- group
- primer
- oligonucleotide
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 claims abstract description 131
- 230000003321 amplification Effects 0.000 claims abstract description 52
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 52
- 239000000523 sample Substances 0.000 claims description 329
- 108091034117 Oligonucleotide Proteins 0.000 claims description 202
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 100
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 97
- 230000008569 process Effects 0.000 claims description 89
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 79
- 230000000295 complement effect Effects 0.000 claims description 60
- 239000012634 fragment Substances 0.000 claims description 52
- 108091093088 Amplicon Proteins 0.000 claims description 38
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 12
- 238000000137 annealing Methods 0.000 claims description 7
- 238000012408 PCR amplification Methods 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 56
- 238000012340 reverse transcriptase PCR Methods 0.000 description 34
- 238000002474 experimental method Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 102000039446 nucleic acids Human genes 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 150000007523 nucleic acids Chemical group 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 238000000605 extraction Methods 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 12
- 239000013642 negative control Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000007403 mPCR Methods 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 6
- 238000011895 specific detection Methods 0.000 description 6
- 238000005382 thermal cycling Methods 0.000 description 6
- -1 15 polymerases Chemical compound 0.000 description 5
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000007837 multiplex assay Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 101100079104 Schizosaccharomyces pombe (strain 972 / ATCC 24843) arm1 gene Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- CTSLUCNDVMMDHG-UHFFFAOYSA-N 5-bromo-3-(butan-2-yl)-6-methylpyrimidine-2,4(1H,3H)-dione Chemical compound CCC(C)N1C(=O)NC(C)=C(Br)C1=O CTSLUCNDVMMDHG-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000003366 endpoint assay Methods 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04291402A EP1602736A1 (en) | 2004-06-04 | 2004-06-04 | HIV type and subtype detection |
| EP04291402.8 | 2004-06-04 | ||
| PCT/EP2005/006513 WO2005118883A1 (en) | 2004-06-04 | 2005-06-03 | Hiv type and subtype detection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005250146A1 AU2005250146A1 (en) | 2005-12-15 |
| AU2005250146B2 true AU2005250146B2 (en) | 2011-02-24 |
Family
ID=34931145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005250146A Ceased AU2005250146B2 (en) | 2004-06-04 | 2005-06-03 | HIV type and subtype detection |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8222382B2 (https=) |
| EP (2) | EP1602736A1 (https=) |
| JP (1) | JP4913042B2 (https=) |
| AT (1) | ATE452996T1 (https=) |
| AU (1) | AU2005250146B2 (https=) |
| CA (1) | CA2567007C (https=) |
| DE (1) | DE602005018474D1 (https=) |
| ES (1) | ES2336807T3 (https=) |
| WO (1) | WO2005118883A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1602736A1 (en) * | 2004-06-04 | 2005-12-07 | Bio-Rad Pasteur | HIV type and subtype detection |
| ES2439951T3 (es) * | 2008-06-06 | 2014-01-27 | F. Hoffmann-La Roche Ag | Detección y cuantificación multiplex de ácidos nucleicos microbianos controlada de forma interna |
| JP5590438B2 (ja) * | 2010-01-29 | 2014-09-17 | 東洋紡株式会社 | 内部コントロール組成物 |
| WO2011112947A1 (en) * | 2010-03-12 | 2011-09-15 | Cenetron Diagnostics Llc | Methods and compositions comprising nucleic acid polymerization enhancers |
| WO2013006684A1 (en) | 2011-07-05 | 2013-01-10 | The Gov. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health And Human Services. | Hiv-1 genotyping assay for global surveillance of hiv-1 drug resistance |
| FR3065967B1 (fr) * | 2017-05-05 | 2022-06-03 | Univ Paris Descartes | Procede in vitro de detection et de quantification de l'adn du vih-2 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712385A (en) * | 1989-07-11 | 1998-01-27 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
| EP0887427A2 (en) * | 1997-06-25 | 1998-12-30 | Ortho-Clinical Diagnostics, Inc. | Amplification and detection of hiv-1 and/or hiv-2 |
| US5962665A (en) * | 1997-06-16 | 1999-10-05 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
| EP1043407A2 (en) * | 1999-04-09 | 2000-10-11 | Diapharm Limited | Nucleotide sequence for detection and characterization of the HIV-1 field isolates participating in the recombination processes directed by the chi sequence |
| WO2003020878A2 (en) * | 2001-09-04 | 2003-03-13 | Abbott Laboratories | Amplification and detection reagents for hiv-1 |
| EP1344837A1 (en) * | 1993-03-26 | 2003-09-17 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| EP1602736A1 (en) * | 2004-06-04 | 2005-12-07 | Bio-Rad Pasteur | HIV type and subtype detection |
-
2004
- 2004-06-04 EP EP04291402A patent/EP1602736A1/en not_active Withdrawn
-
2005
- 2005-06-03 CA CA2567007A patent/CA2567007C/en not_active Expired - Lifetime
- 2005-06-03 AT AT05769801T patent/ATE452996T1/de not_active IP Right Cessation
- 2005-06-03 ES ES05769801T patent/ES2336807T3/es not_active Expired - Lifetime
- 2005-06-03 AU AU2005250146A patent/AU2005250146B2/en not_active Ceased
- 2005-06-03 JP JP2007513883A patent/JP4913042B2/ja not_active Expired - Fee Related
- 2005-06-03 DE DE602005018474T patent/DE602005018474D1/de not_active Expired - Lifetime
- 2005-06-03 EP EP05769801A patent/EP1751317B1/en not_active Expired - Lifetime
- 2005-06-03 WO PCT/EP2005/006513 patent/WO2005118883A1/en not_active Ceased
- 2005-06-03 US US11/628,326 patent/US8222382B2/en not_active Expired - Fee Related
-
2012
- 2012-06-18 US US13/526,469 patent/US9080218B2/en not_active Expired - Lifetime
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712385A (en) * | 1989-07-11 | 1998-01-27 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
| EP1344837A1 (en) * | 1993-03-26 | 2003-09-17 | Gen-Probe Incorporated | Detection of human immunodeficiency virus type 1 |
| US5962665A (en) * | 1997-06-16 | 1999-10-05 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
| EP0887427A2 (en) * | 1997-06-25 | 1998-12-30 | Ortho-Clinical Diagnostics, Inc. | Amplification and detection of hiv-1 and/or hiv-2 |
| EP1043407A2 (en) * | 1999-04-09 | 2000-10-11 | Diapharm Limited | Nucleotide sequence for detection and characterization of the HIV-1 field isolates participating in the recombination processes directed by the chi sequence |
| WO2003020878A2 (en) * | 2001-09-04 | 2003-03-13 | Abbott Laboratories | Amplification and detection reagents for hiv-1 |
Non-Patent Citations (2)
| Title |
|---|
| SCHUTTEN, M. et al., J. Virol. Meth., 2000, vol. 88, pages 81-87 * |
| SWANSON, P. et al., J. Virol. Meth., 2000, vol. 89, pages 97-108 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1602736A1 (en) | 2005-12-07 |
| US20080318205A1 (en) | 2008-12-25 |
| DE602005018474D1 (de) | 2010-02-04 |
| CA2567007C (en) | 2015-04-28 |
| WO2005118883A1 (en) | 2005-12-15 |
| EP1751317B1 (en) | 2009-12-23 |
| US8222382B2 (en) | 2012-07-17 |
| US9080218B2 (en) | 2015-07-14 |
| US20120283131A1 (en) | 2012-11-08 |
| ATE452996T1 (de) | 2010-01-15 |
| ES2336807T3 (es) | 2010-04-16 |
| JP4913042B2 (ja) | 2012-04-11 |
| EP1751317A1 (en) | 2007-02-14 |
| JP2008501328A (ja) | 2008-01-24 |
| CA2567007A1 (en) | 2005-12-15 |
| AU2005250146A1 (en) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5205346B2 (ja) | Ｈｉｖ−１の増幅及び検出試薬 | |
| US8192939B2 (en) | Universal multi-variant detection system | |
| US20110311971A1 (en) | Rt-late-pcr | |
| US9080218B2 (en) | HIV type and subtype detection | |
| WO2012060779A1 (en) | Method for detection of enterovirus ev71 | |
| JP4571857B2 (ja) | Ｂ型肝炎ウイルスの核酸の検出および定量のためのポリヌクレオチド | |
| CN111926119A (zh) | 一种用于检测新型冠状病毒的核酸检测试剂盒及其使用方法 | |
| EP3214181B1 (en) | Oligonucleotides, set of oligonucleotides, htlv-i/htlv-ii infection diagnostic and discrimination kit, polynucleotide suitable as reference target for designing primers and probes for the detection and differentiation of htlv-i and htlv-ii, amplicon and method for detecting at least one htlv target | |
| US20170058366A1 (en) | Hiv-2 nucleic acids and methods of detection | |
| Althaus et al. | Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance | |
| KR102653475B1 (ko) | 코로나 바이러스 동시 검출용 조성물 및 검출 방법 | |
| RU2584573C2 (ru) | Способы, композиции и наборы для определения вируса иммунодефицита человека (вич) | |
| US20110236892A1 (en) | Method for lowering the dependency towards sequence variation of a nucleic acid target in a diagnostic hybridization assay | |
| KR20060041664A (ko) | 노로바이러스 검출 시약 | |
| US10113206B2 (en) | Methods, compositions, and kits for determining human immunodeficiency virus (HIV) | |
| HK40047605A (en) | Compositions and methods for amplifying, detecting or quantifying human polyomavirus bk virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: BIO-RAD EUROPE GMBH Free format text: FORMER OWNER(S): BIO-RAD INNOVATIONS |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |